Overview

Intra-venous Zoledronic Acid Once Yearly

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment. Zoledronic acid will be compared to oral bisphosphonates (OBP) with respect to the change in Bone Mineral Density (BMD) and incidence of fractures.
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Diphosphonates
Zoledronic Acid